First test: how liver health affects new drug
NCT ID NCT06336018
Summary
This early-stage study looked at how a single dose of an experimental drug called etavopivat is processed by the body in people with different levels of liver function. It involved 48 adults, some with stable liver disease and some with healthy livers, to compare drug levels and safety. The main goal was to understand if liver problems change how the drug works in the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Amer. Rrsch Corp-TX Liver Inst
San Antonio, Texas, 78215, United States
-
Orlando Clinical Research Center
Orlando, Florida, 32806, United States
-
Orlando Clinical Research Center
Orlando, Florida, 32809, United States
Conditions
Explore the condition pages connected to this study.